Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 701–800 of 1,001
Risk Stratification in Acute Pulmonary Embolism: The Latest Algorithms
Triantafyllou, G. A., O’Corragain, O. A., Rivera‐Lebron, B. N., & Rali, P. M. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1722898 · Cited by 15
Mavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 16
Bhatt, M. D., Portman, M. A., Berger, F. F., Jacobs, J. P., Newburger, J. W., Duggal, A., GROSSO, M. A., Pandya, G., Dave, J., & Goldenberg, N. A. (2021) · Cardiology in the Young · doi:10.1017/s1047951121002523 · Cited by 15
Delluc, A., Ghanima, W., Kovacs, M. J., Shivakumar, S., Kahn, S. R., Sandset, P. M., Kearon, C., Mallick, R., & Rodger, M. A. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15537 · Cited by 16
Nakano, Y., Adachi, S., Nishiyama, I., Yasuda, K., Imai, R., Yoshida, M., Iwano, S., Kondo, T., Murohara, T., Ando, M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15636 · Cited by 15
Martín, A. J. M., Gallardo, E., Agnelli, G., Crespo, C., Forghani, M., Arumí, D., de Cabo, S. F., & Soto, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2087998 · Cited by 17
Verma, A., Kumar, P., Pauly, I., Singh, A. K., Kumar, A., Singh, Y., Thareja, S., & Kamal, M. A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221107123841 · Cited by 15
Parker, K., Choudhuri, S., Lewis, P. J., Thachil, J. V., & Mitra, S. (2023) · BMC Nephrology · doi:10.1186/s12882-022-03041-w · Cited by 23
Amin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.10.965 · Cited by 17
Warfarin Therapy: Survey of Patients' Knowledge of their Drug Regimen.
Shuaib, W., Iftikhar, H., Alweis, R. L., & Shahid, H. (2014) · PubMed · Cited by 19
Wakakura, S., Hara, F., Fujino, T., Hamai, A., Ohara, H., Kabuki, T., Harada, M., & Ikeda, T. (2017) · International Heart Journal · doi:10.1536/ihj.16-482 · Cited by 16
the COMMAND VTE Registry Investigators, Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1791-2 · Cited by 16
Self-citationHosokawa, K., Abe, K., & Tsutsui, H. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.018 · Cited by 15
Weycker, D. A., Wygant, G. D., Guo, J. D., Lee, T. T. H., Luo, X., Rosenblatt, L. C., Mardekian, J., Atwood, M., Hanau, A., & Cohen, A. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001081 · Cited by 16
Lopes, D. G., Tamayo, A., Schipp, B., & Siepmann, T. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.08.014 · Cited by 18
Coons, E. M., Staubes, B. A., Casey, A. L., Elagizi-Youssef, S. A., Mohammed, A., Sharma, N., & Kline, E. R. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211025050 · Cited by 16
Edoxaban, a Novel Oral Factor Xa Inhibitor
Minor, C., Tellor, K. B., & Armbruster, A. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015579426 · Cited by 16
“The study included patients with a diagnosis of an acute, symptomatic DVT, a PE, or both.(31) Patients were excluded if they had a contraindication to heparin or warfarin, received therapeutic doses of heparin for more than 48 hours, received more than 1 dose of warfarin, were on aspirin therapy >100 mg or dual antipl…”
BackgroundResultGreen, B., Mendes, R. A., der Valk, R. V., & Brennan, P. A. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12441 · Cited by 17
Doundoulakis, I., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200506114450 · Cited by 14
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Effects of oral anticoagulant therapy in patients with pulmonary diseases
Lai, J., Feng, S., Xu, S., & Liu, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.987652 · Cited by 15
Almajdi, A., Almutairi, S., & Alharbi, M. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.027 · Cited by 15
Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory
Blann, A. D. (2014) · British Journal of Biomedical Science · doi:10.1080/09674845.2014.11669981 · Cited by 14
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism
Vanassche, T., Vandenbriele, C., Peerlinck, K., & Verhamme, P. B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.999043 · Cited by 16
Novel Anticoagulant Agents in the Perioperative Setting
Lemay, A., Kaye, A. D., & Urman, R. D. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.01.016 · Cited by 14
Thrombosis of atypical location: how to treat patients in the era of direct oral anticoagulants?
Mimier, M. K., Janczak, D. T., McBane, R. D., Houghton, D. E., & Wysokiński, W. E. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4333 · Cited by 18
The prevention of venous thromboembolism recurrence in the elderly: a still open issue
Palareti, G., & Poli, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1526667 · Cited by 14
Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
Crawley, R. M., & Anderson, R. L. (2020) · Drugs · doi:10.1007/s40265-020-01345-5 · Cited by 15
Riess, H. B., Verhamme, P. B., Weitz, J. I., Young, A., Bauersachs, R. M., Beyer‐Westendorf, J., Crowther, M. A., & Maraveyas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103125 · Cited by 15
Palareti, G., Antonucci, E., Legnani, C., Mastroiacovo, D., Poli, D., Prandoni, P., Tosetto, A., Pengo, V., Testa, S., & Ageno, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040449 · Cited by 15
Yasuda, M., Yamanaka, Y., Kano, H., Araki, N., Ishikawa, H., Ikeda, J., & Kuwabara, S. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7320-21 · Cited by 14
“Since she had heavy menstrual bleeding, we choose edoxaban, a direct oral anticoagulant considered safer than warfarin (10, 11).”
BackgroundReview article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis
Ma, J., Chalasani, N., Schwantes-An, T.-H. L., & Bjornsson, E. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17297 · Cited by 14
Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s88088 · Cited by 19
Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Blann, A. D., & Lip, G. Y. H. (2016) · Heart · doi:10.1136/heartjnl-2014-307019 · Cited by 15
Management of bleeding complications in patients with cancer on DOACs
Schulman, S., Shrum, J., & Majeed, A. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30113-x · Cited by 16
“The largest studies were randomized trials that compared DOACs to standard of care for the management of VTE [8,9,17,18,28,29].”
BackgroundWu, C. M., McMurtry, M. S., Sandhu, R. K., Youngson, E. R. E., Ezekowitz, J. A., Kaul, P., & McAlister, F. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140607 · Cited by 18
Edoxaban (Savaysa): A Factor Xa Inhibitor.
Chan, L., & Pisano, M. (2015) · Europe PMC (PubMed Central) · Cited by 14
Uterine bleeding during anticoagulation in women with venous thromboembolism
Moustafa, F., Fernández, S. M., Fernández‐Capitán, C., Nieto, J. A., Pedrajas, J. M., Visonà, A., Valero, B., Marchena, P. J., Braester, A., & Monréal, M. (2017) · Thrombosis Research · doi:10.1016/s0049-3848(17)30058-0 · Cited by 16
Jujo, T., Tanabe, N., Sakao, S., Sugiura, T., Sekine, A., Nishimura, R., Suda, R., Naito, A., Miwa, H., Yamamoto, K., et al. (2017) · Pulmonary Circulation · doi:10.1177/2045893217717258 · Cited by 14
Roldan, T., Blanco, J. J. R., Villamañán, E., & Waxman, A. B. (2017) · Pulmonary Circulation · doi:10.1177/2045893217721903 · Cited by 14
“Hokusai-VTE et al.(16) RCT (n1⁄4 4122) 2013 VTE 2.”
Bauersachs, R. M., Agnelli, G., Gitt, A. K., Monréal, M., Mismetti, P., Willich, S. N., Laeis, P., Fronk, E., Bramlage, P., & Cohen, A. T. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.029 · Cited by 15
Pritchard, E. R., Murillo, J. R., Putney, D. R., & Hobaugh, E. C. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217726158 · Cited by 14
Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents
Fusco, S. A. D., Lucà, F., Benvenuto, M., Iorio, A., Fiscella, D., D’Ascenzo, F., Madeo, A., Colivicchi, F., Lenarda, A. D., & Gulizia, M. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.060 · Cited by 15
Coleman, C. I., Peacock, W. F., Bunz, T. J., & Beyer‐Westendorf, J. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.05.031 · Cited by 15
Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
Kim, S., Yhim, H., & Bang, S. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e52 · Cited by 17
Gustafsson, N., Poulsen, P. B., Stallknecht, S. E., Dybro, L., & Johnsen, S. P. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz035 · Cited by 16
the COMMAND VTE Registry Investigators, Oi, M., Yamashita, Y., Toyofuku, M., Morimoto, T., Motohashi, Y., Tamura, T., Kaitani, K., Amano, H., Takase, T., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01964-0 · Cited by 14
Self-citationSchenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 14
Sandblad, K. G., Schulman, S., Rosengren, A., Sörbo, J., Philipson, J., & Hansson, P. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13712 · Cited by 13
Ikeda, N., Yamashita, Y., Morimoto, T., Chatani, R., Kaneda, K., Nishimoto, Y., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035997 · Cited by 15
“20–26 In addition, DOACs might be more effective in terms of thrombus resolution compared with warfarin, which could have a beneficial effect in preventing development of CTEPH after acute PE.”
Self-citationResuming anticoagulation after hemorrhage: A practical approach
Colantino, A., Jaffer, A. K., & Brotman, D. J. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14047 · Cited by 35
Rankin, J., Nagar, M., Crosby, J., Toomari, N., Pietras, R. J., & Ben-Zur, U. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-1135-9 · Cited by 13
“Similarly, the AMPLIFY and Hokusai-VTE trials showed non-inferiority of apixaban and edoxaban, respectively, when compared with warfarin in the treatment of VTE, with a significant reduction in bleeding events [9, 10].”
MethodVoigtlaender, M., & Länger, F. P. (2017) · Hämostaseologie · doi:10.5482/hamo-16-09-0036 · Cited by 14
Approaches to Direct Oral Anticoagulant Selection in Practice
Paravattil, B., & Elewa, H. F. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418793137 · Cited by 16
Farge, D., & Frère, C. (2019) · F1000Research · doi:10.12688/f1000research.18673.1 · Cited by 15
Zhou, L., Ding, Y., Gao, Y., Yang, B., Bao, J., & Ma, J. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1711883 · Cited by 13
Chaudhary, R., Pagali, S. R., Garg, J., Murad, M. H., Wysokiński, W. E., & McBane, R. D. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16549 · Cited by 15
“(RECOVER and RECOVER II)(22); two trials compared rivaroxaban with VKAs (n = 1,283) (EINSTEIN-DVT and EINSTEIN-PE)(23,24); one trial compared apixaban with VKAs (n = 749) (AMPLIFY)(25); and one trial compared edoxaban with VKAs (n = 1,104) (HOKUSAI-VTE).(26) The patient-level data were unavailable for the older adult…”
BackgroundYami, M. S. A., Badreldin, H. A., Mohammed, A. H., Elmubark, A., Alzahrani, M., & Alshehri, A. M. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1696-0 · Cited by 15
“The Hokusai-VTE trial was excluded since the efficacy and safety outcomes of rivaroxaban in patients with cancer were reported in the post-hoc analysis of the Hokusai-VTE trial in order to avoid overlapping of patients [10].”
MethodSafieddine, M., Chapelle, C., Ollier, É., Ferdynus, C., Bertoletti, L., Mismetti, P., Cucherat, M., & Laporte, S. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.10.013 · Cited by 14
Acute pulmonary embolism: risk assessment, risk stratification and treatment options
Piovella, F., & Iosub, D. I. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12264 · Cited by 16
Pulmonary embolism: current and new treatment options
Walter, R. J., Moores, L. K., & Jiménez, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.936931 · Cited by 13
MORISHIMA, Y., Kamisato, C., & Honda, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.020 · Cited by 14
Nyberg, J., Karlsson, K. E., Jönsson, S., Yin, O., Miller, R., Karlsson, M., & Simonsson, U. S. H. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12077 · Cited by 13
Kabrhel, C. (2017) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1597760 · Cited by 15
Update on diagnosis and anticoagulant therapy for venous thromboembolism
Stevens, H., & Tran, H. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.14063 · Cited by 13
Michida, M., Ishikawa, H., Kaneda, T., Tatekabe, S., & Nakamura, Y. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.8b00413 · Cited by 13
Acute Perioperative Pulmonary Embolism—Management Strategies and Outcomes
Cormican, D. S., Morkos, M. S., Winter, D., Rodrigue, M. F., Wendel, J., & Ramakrishna, H. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.11.018 · Cited by 13
In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution
Angheloiu, A. A., Tan, Y., Ruse, C. I., Shaffer, S. A., & Angheloiu, G. O. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00308-1 · Cited by 13
Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates.
Wang, K.-L., Kao, Y., Chang, W., Chang, H., Huang, W. C., Hsu, P., Hsu, C., Huang, C.-L., Hsieh, L., Wang, C.-Y., et al. (2020) · PubMed Central · doi:10.6515/acs.202011_36(6).20200917a · Cited by 15
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?
Verhamme, P. B., & Bounameaux, H. (2013) · Circulation · doi:10.1161/circulationaha.113.007478 · Cited by 14
“The results of all 4 DOACs for the acute treatment of VTE are summarized in Table 1.(4-8)”
BackgroundQuon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Alshaya, O. A., Korayem, G. B., Yami, M. S. A., Qudayr, A. H., Althewaibi, S., Fetyani, L., Alshehri, S. D., Alnashmi, F., Albasseet, M., Alshehri, L. A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010199 · Cited by 12
Safety and efficacy of oral anticoagulants in extreme weights
Chin-Hon, J., Davenport, L., Huang, J. C., Akerman, M. B., & Hindenburg, A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.001 · Cited by 12
Andexanet Alfa–Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives
Chabata, C. V., Yu, H., Ke, L., Frederiksen, J. W., Patel, P. A., Sullenger, B. A., & Thalji, N. K. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321650 · Cited by 15
Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians
Abo‐Salem, E., & Becker, R. C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1060-y · Cited by 12
“or a body weight below 60 kg [6].”
BackgroundAnticoagulation strategies for venous thromboembolism: moving towards a personalised approach
Cohen, A. T., & Black, S. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1028 · Cited by 16
Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations
van Es, N., & Buller, H. R. (2015) · Hematology · doi:10.1182/asheducation-2015.1.125 · Cited by 14
Honda, Y., Kamisato, C., & MORISHIMA, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.011 · Cited by 12
Update on the Treatment of Venous Thromboembolism
Schulman, S. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1592305 · Cited by 14
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 14
Reversal strategies in patients treated with direct oral anticoagulants
Gressenberger, P. (2019) · VASA · doi:10.1024/0301-1526/a000777 · Cited by 14
Park, H., Kang, D., Ahn, J., Kim, K. W., Wong, Y. T. A., Lam, S. C. C., Yin, W., Wei, J., Lee, Y., Kao, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042587 · Cited by 12
Edoxaban in cardiovascular disease management: Review
Srinivasan, S., Ajmal, M., Pecci, C., & Lassar, T. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15026 · Cited by 15
“Edoxaban was non-inferior to the standard therapy with significantly fewer bleeding events.(23) It is also worth mentioning that”
BackgroundAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 14
Tsai, S. H. L., Hu, C.-W., Shao, S., Tischler, E. H., Obisesan, O. H., Vervoort, D., Chen, W., Hu, J., & Kuo, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.896952 · Cited by 13
Wu, S., Lv, M., Chen, J., Jiang, S., Chen, M., Fang, Z., Zeng, Z., Qian, J., Xu, W., Guan, C., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07433-4 · Cited by 15
Haas, S. K., Farjat, A. E., Pieper, K. S., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Goldhaber, S. Z., Goto, S., Mantovani, L. G., Prandoni, P., et al. (2022) · TH Open · doi:10.1055/s-0042-1757744 · Cited by 13
Toyoda, Ḱ., Arakawa, S., Ezura, M., Kobayashi, R., Tanaka, Y., Hasegawa, S., Yamashiro, S., Komatsu, Y., Terasawa, Y., Masuno, T., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64223 · Cited by 12
“However, oral anticoagulants may lead to or worsen acute major bleeding, which in turn can be associated with significant complications, including death 4-9 ) .”
BackgroundHull, R. D., & Gersh, M. H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.975786 · Cited by 13
Phillippe, H. M., Wright, B. M., Bowerman, K. E., & Andrus, M. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516672693 · Cited by 12
“Rivaroxaban and apixaban showed a lower incidence of major bleeding when compared to warfarin therapy, and all 4 agents had a lower incidence of intracranial hemorrhage when compared to warfarin.(19-24) Dabigatran had a higher incidence of GI bleed when compared to warfarin therapy.”
BackgroundSafety of warfarin in “high-risk” populations: A meta-analysis of randomized and controlled trials
Minno, M. N. D. D., Ambrosino, P., & Dentali, F. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.005 · Cited by 14
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.
Amin, A. (2016) · PubMed · Cited by 14
Rosenthal, C., von Heymann, C., & Koscielny, J. (2017) · Hämostaseologie · doi:10.5482/hamo-16-10-0041 · Cited by 14
Chopard, R., Andarelli, J. N., Humbert, S., Falvo, N., Morel-Aleton, M., Bonnet, B., Napporn, G., Kalbacher, E., Obert, L., Degano, B., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.12.013 · Cited by 12
What gastroenterologists should know about direct oral anticoagulants
Radaelli, F., Fuccio, L., Paggi, S., Bono, C. D., Dumonceau, J., & Dentali, F. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.04.032 · Cited by 13
Ikeda, N., Amemiya, K., Sato, S., Iijima, R., Hara, H., & Nakamura, M. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01799-x · Cited by 12
“Clinically relevant bleeding was defined as major bleeding as described by the International Society on Thrombosis and Haemostasis (ISTH), and clinically relevant nonmajor bleeding was defined as described in the Hokusai-VTE trial [13, 14].”
MethodMORISHIMA, Y., & Honda, Y. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01851-8 · Cited by 12
Gu, Z., Yan, Y., Yang, S.-Y., Shen, L., Kong, L.-C., Zhang, C., Wei, A., Li, Z., Wang, X., & Lin, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.152 · Cited by 12
Sorigué, M., Cañamero, E., Sigüenza, P., Nomdedéu, M., & López-Núñez, J. J. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1713321 · Cited by 13
Edoxaban versus Warfarin for Venous Thromboembolism
Buller, H. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1313883 · Cited by 12
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.